Gerd R Burmester - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Gerd R Burmester's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Gerd R Burmester
Verified
Contributor, Annals of the Rheumatic Diseases
Berlin
Beats
Gambling, Adult Content
Content
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
By Gerd R Burmester, John R.P. Tesser, Anna Shmagel, Yanxi Liu| The Journal of Rheumatology Verified Key Indexing Terms:arthritisclinical trialsRheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects joints, causes progressive bone and cartilage damage, and impairs quality of life if treated inadequately.1,2 The primary goal of RA therapy is to achieve sustained remission or low disease activity (LDA).
By Justin Cooper, Shenaz Bagha Verified, Gerd R Burmester| Healio Verified You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: The initial clinical outcomes of upadacitinib for RA “improved or were maintained” through 5 years. Major adverse cardiovascular events and venous thromboembolisms were infrequent.
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
By Gerd R Burmester, John R.P. Tesser, Anna Shmagel, Yanxi Liu| The Journal of Rheumatology Verified Key Indexing Terms:arthritisclinical trialsRheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects joints, causes progressive bone and cartilage damage, and impairs quality of life if treated inadequately.1,2 The primary goal of RA therapy is to achieve sustained remission or low disease activity (LDA).
Company Info
Annals of the Rheumatic Diseases
Berlin, Berlin, Germany
+49 30 45050